Revive Therapeutics Ltd. (CVE:RVV) | WebDisclosure

Switch to English

10966	Sociétés
240146	Mots-clés
168912	Articles
129234	Communiqués

Accueil
Sociétés
Revive Therapeutics Ltd.

COMMUNIQUÉ DE PRESSE

publié le 20/05/2026 à 13:45, il y a 3 mois 23 jours

Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures
Revive Therapeutics Ltd. announces strategic expansion plan for bucillamine, a potential asset for infectious diseases, nerve-agent exposure, pandemics, and medical countermeasures. Company aims to advance preclinical studies and pursue government partnerships

Preclinical Studies Infectious Diseases Government Partnerships Bucillamine Revive Therapeutics
BRÈVE

publiée le 11/03/2026 à 12:35, il y a 6 mois 1 jour

Revive Therapeutics Expands Bucillamine's Patent Portfolio in North America

Patent Portfolio Infectious Diseases Bucillamine Nerve Agent Revive Therapeutics
BRÈVE

publiée le 11/03/2026 à 12:35, il y a 6 mois 1 jour

Revive Therapeutics étend le portefeuille de brevets de la bucillamine en Amérique du Nord

Portefeuille De Brevets Maladies Infectieuses Bucillamine Revive Therapeutics Agent Neurotoxique
COMMUNIQUÉ DE PRESSE

publié le 11/03/2026 à 12:30, il y a 6 mois 1 jour

Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases
Revive Therapeutics announces key patent milestones for Bucillamine in medical countermeasures and infectious diseases, strengthening its strategic position

Medical Countermeasures Infectious Diseases Bucillamine Revive Therapeutics Patent Milestones

Les Echos

Publié le 11/09/2026 à 07:00, il y a 1 jour 11 heures

Transparantiekennisgeving van Baltisse Groep
Publié le 11/09/2026 à 07:00, il y a 1 jour 11 heures

Transparency notification by Baltisse Group
Publié le 11/09/2026 à 07:00, il y a 1 jour 11 heures

BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Publié le 11/09/2026 à 07:00, il y a 1 jour 11 heures

BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Publié le 10/09/2026 à 19:30, il y a 1 jour 23 heures

Availability of the 2026 Interim Financial Report

Voir tout LES ECHOS COMFI WIRE

Accesswire

Publié le 12/09/2026 à 02:35, il y a 16 heures 1 minute

Gamma Resources Announces Extension of Private Placement Closing Date
Publié le 11/09/2026 à 23:00, il y a 19 heures 36 minutes

Rio Grande Resources Engages Machai Capital for Investor Outreach
Publié le 11/09/2026 à 22:05, il y a 20 heures 31 minutes

Usha Resources Announces Leadership Transition
Publié le 11/09/2026 à 21:25, il y a 21 heures 11 minutes

Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Publié le 11/09/2026 à 17:00, il y a 1 jour 1 heure

Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors

Voir tout ACCESSWIRE

EQS Group

Publié le 12/09/2026 à 17:50, il y a 45 minutes

New Delhi Marks UN Day for South-South Cooperation with Push to Scale Dryland Innovation Across the Global South
Publié le 12/09/2026 à 07:30, il y a 11 heures 5 minutes

NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Publié le 11/09/2026 à 22:15, il y a 20 heures 20 minutes

Amrize Appoints Mario Gross as President of Building Envelope
Publié le 11/09/2026 à 22:10, il y a 20 heures 25 minutes

Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Publié le 11/09/2026 à 19:44, il y a 22 heures 51 minutes

DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031